Julie Schwedock from Takeda Pharmaceuticals speaks about LBPs: What to consider when choosing CDMOs.

Julie Schwedock from Takeda Pharmaceuticals speaks about LBPs: What to consider when choosing CDMOs.

Julie Schwedock, PhD is Associate Director of the Microbial Development Team at Takeda Pharmaceuticals.  She leads a cross-functional Pharmaceutical Sciences team for Live Bacterial Products (LBPs) focused on treating dysbiosis of the gut microbiome.  She also heads a functional line group that works on process development for microbial expression systems as well as LPBs.  Prior to that she was Associate Director of Analytical Development and QC at Vedanta Biosciences, also working with LBPs, where she developed analytics in an uncertain regulatory landscape for a product now in Ph2 clinical trials. …

Read More